 |
 |
 |
|
Irisin, a secreted myokine, is a circulating biomarker for metabolic syndrome. This new Irisin Elisa kit was formulated by the glycosylated human irisin derived from HEK293 cells and specific monoclonal antibody. The antibody was validated by the glycosylated human irisin derived from HEK293 cells and human serum samples on western blot.
Citations:
- Gonzalez-Gil AM, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome. Diabetol Metab Syndr. 2019 Aug 5;11:63. doi: 10.1186/s13098-019-0458-2. eCollection 2019
- Anna S. Huerta-Delgado, et al, "Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome", Journal of Diabetes Research, vol. 2020, Article ID 1949415, 16 pages, 2020.
- Śliwicka E, et al. Effects of marathon race on selected myokines and sclerostin in middle-aged male amateur runners. Sci Rep. 2021 Feb 2;11(1):2813.
- Dr. Zheng-ping Zhang, et al. Serum irisin associated with breast cancer to spinal metastasis. Medicine (2018) 97:17 http://dx.doi.org/10.1097/MD.0000000000010524
- Zhang, Feng et al. “Serum Irisin as a Potential Biomarker for Cognitive Decline in Vascular Dementia.” Frontiers in neurology vol. 12 755046. 13 Sep. 2021, doi:10.3389/fneur.2021.755046
|
|
|
 |
|
 |
|